The design of cobalt(III) complexes of phenazine-1-carboxamides as prointercalators and potential hypoxia-selective cytotoxins

Anti-Cancer Drug Design

Volumn 14, Issue 3, 1999, Pages 231-241

  Perrin, Leah C ^a   Wilson, William R ^b   Denny, William A ^c   McFadyen, W David ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Cobalt(III); DNA binding; Hypoxic selectivity; Phenazine; Prodrug; Prointercalator

Indexed keywords

AMIDE; ANTINEOPLASTIC AGENT; COBALT COMPLEX; CYTOTOXIN; INTERCALATING AGENT; PHENAZINE DERIVATIVE; PRODRUG;

ARTICLE; CYTOTOXICITY; DNA BINDING; DRUG ACTIVATION; DRUG DESIGN; HYPOXIA; LIGAND BINDING; PRIORITY JOURNAL;

ANIMALS; ANOXIA; ANTINEOPLASTIC AGENTS; CHELATING AGENTS; COBALT; CRICETINAE; CRICETULUS; DNA; ELECTROCHEMISTRY; GROWTH INHIBITORS; INTERCALATING AGENTS; KINETICS; MICE; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; ORGANOMETALLIC COMPOUNDS; PHENAZINES;

EID: 0032842684     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Abrahams B.F., Hoskins B.F., McFadyen W.D., Perrin L.C. (1998) Tris(O, O′-3-methyl-2,4-pentanedionato)cobalt(III). Acta Crystallographica, C54, 1807.
2. Anderson R.F., Denny W.A., Ware D.C., Wilson W.R. (1996) Pulse radiolysis studies on the mechanism of hypoxia-selective cytotoxicity of the cobalt(III)-nitrogen mustard complex SN 24771. British Journal of Cancer, 74 (suppl. 27), 48.
3. Brodsky A.E., Gordienko L.L., Degtiarev L.S. (1968) Cathodic reduction of some aromatic compounds to free anion-radicals. Electrochimica Acta, 13, 1095.
4. Denny W.A. (1989) DNA-intercalating agents as antitumour drugs: prospects for future design. Anti-Cancer Drug Design, 4, 241.
5. Denny W.A., Wilson W.R., Hay M.P. (1996) Recent developments in the design of bioreductive drugs. British Journal of Cancer, 74 (suppl. XXVII), 32.
6. Finlay G.J., Baguley B.C., Wilson W.R. (1984) A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. Analytical Biochemistry, 139, 272.
7. Hoy C.A., Thompson L.H., Mooney C.L., Salazar E.P. (1985) Defective DNA cross-link removal in Chinese hamster cell mutants hypersensitive to bifunctional intercalating agents. Cancer Research, 45, 1737.
8. Manning G.S. (1978) The molecular theory of polyelectrolyte solutions with applications to the electrostatic properties of polynucleotides. Quarterly Reviews of Biophysics, 11, 179.
9. McFadyen W.D., Wakelin L.P.G., Roos I.A.G., Hillcoat B.L. (1986) Binuclear platinum (II)-terpyridine complexes. The Biochemical Journal, 238, 757.
10. McFadyen W.D., Wakelin L.P.G., Roos I.A.G., Hillcoat B.L. (1987) The binding of binuclear platinum(II)-terpyridine complexes to DNA. The Bicohemical Journal, 242, 177.
11. McGhee J.D., Von Hippel P.H. (1974) Theoretical aspects of DNA-protein interactions: co-operative and non-co-operative binding of large ligands to a one dimensional homogeneous lattice. Journal of Molecular Biology, 86, 469.
12. Patterson L.H., Craven M.R., Fisher G.R., Teesdale-Spittle P. (1995) Aliphatic amine-N-oxides of DNA binding drugs as bioreductive agents. Oncology Research, 6, 533.
13. Rewcastle G.W., Denny W.A., Baguley B.C. (1987) Potential antitumour agents. 51. Synthesis and antitumor activity of substituted phenazine-1-carboxamides. Journal of Medicinal Chemistry, 30, 843.
14. Rockwell S. (1992) Use of hypoxia-directed drugs in therapy of solid tumors. Seminars in Oncology, 19, 29.
15. Siim B.G., Pruijn F.B., Denny W.A., Wilson W.R. (1997) Nitro reduction as an electronic switch for bioreductive drug activation. Oncology Research, 9, 357.
16. Simic M., Lilie J. (1974) Kinetics of ammonia detachment from reduced cobalt(III) complexes based on conductometric pulse radiolysis. Journal of the American Chemical Society, 96, 291.
17. Springer C.J., Dowell R., Burke P.J., Davies H.D., Blakey D.C., Melton R.G., Niculescu-Duvaz I. (1995) Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme-prodrug therapy (ADEPT). Journal of Medicinal Chemistry, 38, 5051.
18. Tietze L.F., Neumann M., Mollers T., Fischer R., Glusenkamp K.-H., Rajewsky M., Jahde E. (1989) Proton-mediated liberation of aldophosphamide from a non-toxic prodrug: a strategy for tumor-selective activation of cytocidal drugs. Cancer Research, 49, 4179.
19. Trinh Q.T., Austin E.A., Murray D.M., Knick V.C., Huber B.E. (1995) Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Research, 55, 4808.
20. Wakelin L.P.G. (1986) Polyfunctional DNA intercalating agents. Medicinal Research Reviews, 6, 275.
21. Wakelin L.P.G. (1990) In Comprehensive Medicinal Chemistry, Vol. 2: DNA Intercalating Agents. Sammes P.G., Taylor J.B. (eds), p. 703. Pergamon Press: Oxford.
22. Ware D.C., Palmer B.D., Wilson W.R., Denny W.A. (1993) Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins. Synthesis and evaluation of cobalt(III) complexes of bidentate mustards. Journal of Medicinal Chemistry, 36, 1839.
23. Wilson W.R., Ferry D.M., Tercel M., Anderson R.F., Denny W.A. (1998) Reduction of nitroarylmethyl quaternary ammonium prodrugs of mechlorethamine by radiation. Radiation Research, 149, 237.
24. Workman P., Stratford I.J. (1993) The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Reviews, 12, 73.